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Abstract
Latent membrane protein 2A (LMP2A), expressed in most Epstein-Barr virus (EBV)-associated malignancies, has been
demonstrated to be responsible for the maintenance of latent infection and epithelial cell transformation. Besides, it could
also act as the target for a CTL-based therapy for EBV-associated malignancies. In the present study, sequence variations of
LMP2A in EBV-associated gastric carcinoma (EBVaGC) and healthy EBV carriers from Guangzhou, southern China, where
nasopharyngeal carcinoma (NPC) is endemic, were investigated. Widespread sequence variations in the LMP2A gene were
found, with no sequence identical to the B95.8 prototype. No consistent mutation was detected in all isolates. The
immunoreceptor tyrosine-based activation motif (ITAM) and PY motifs in the amino terminus of LMP2A were strictly
conserved, suggesting their important roles in virus infection; while 8 of the 17 identified CTL epitopes in the
transmembrane region of LMP2A were affected by at least one point mutation, which may implicate that the effect of
LMP2A polymorphisms should be considered when LMP2A-targeted immunotherapy is conducted. The polymorphisms of
LMP2A in EBVaGC in gastric remnant carcinoma (GRC) were for the first time investigated in the world. The LMP2A sequence
variations in EBVaGC in GRC were somewhat different from those in EBVaGC in conventional gastric carcinoma. The
sequence variations of LMP2A in EBVaGC were similar to those in throat washing of healthy EBV carriers, indicating that
these variations are due to geographic-associated polymorphisms rather than EBVaGC-associated mutations. This, to our
best knowledge, is the first detailed investigation of LMP2A polymorphisms in EBVaGC in Guangzhou, southern China,
where NPC is endemic.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous herpes virus that was
originally identified in a human Burkitt lymphoma cell line [1]. It
is implicated in the etiology of human lymphoid neoplasms
including Burkitt lymphoma, Hodgkin lymphoma, and B-cell
lymphomas among immunosuppressed patients [2]. EBV has also
been suspected to cause epithelial malignancies such as nasopha-
ryngeal carcinoma (NPC) and a subset of gastric carcinoma which
is defined as EBV-associated gastric carcinoma (EBVaGC) [2].
EBVaGC represents about 10% of gastric carcinoma worldwide;
however, the frequency varies from country to country and ranges
from 1.3% to 20.1% [3,4,5]. The first large study (.500 cases) was
conducted in Japan, in which EBVaGC accounted for 6.9% of the
cases (67 of 970 cases) [6]. Besides Japan, van Beek et al. [7]
detected 41 (7.2%) EBVaGCs out of 566 gastric carcinoma cases
in the Netherlands. In our preliminary study, we found that the
proportion of EBVaGC in gastric carcinoma in Guangzhou,
southern China was 6.7% (45/676). According to a recent meta-
analysis, the pooled estimate of frequency of EBVaGC in gastric
carcinoma in America, Europe and Asia was 9.9%, 9.2% and
8.3%, respectively [8].
After infection, EBV persists in host in latency cycle and
constitutively expresses a limited set of viral gene products, the so-
called latent products, which comprise six EBV nuclear antigens
(EBNAs 1, 2, 3A, 3B, 3C and -LP), three latent membrane
proteins (LMPs 1, 2A and 2B), two EBV-encoded small non-
coding RNAs (EBERs 1 and 2) and the BamHI A rightward
transcripts (BARTs) [9]. Three latency patterns have been
described depending on which of these latent products are
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EBNA1 expression; latency II includes LMP1 and LMP2 in
addition; and latency III is defined by expression of EBERs,
BARTs, all six EBNA proteins and three LMP proteins [9].
EBVaGC belongs to latency I. However, zur Hausen et al. [10],
Sugiura et al. [11] and Luo et al. [12] examined the viral gene
expression in EBVaGCs at the mRNA level and found that
LMP2A mRNA was detected in 7 of 9 (77.8%), 3 of 7 (42.9%) and
4 of 11 (36.4%) cases, respectively. In addition, zur Hausen et al.
[10] also found that BARF1 mRNA were expressed in 9 of 9
(100%) EBVaGC cases.
LMP2A consisting of 497 amino acids (aa) is encoded by LMP2
gene, whose mRNA containing 9 exons [13]. LMP2A includes a
119 aa cytoplasmic amino-terminal domain, 12 hydrophobic
transmembrane domains and a 27 aa cytoplasmic carboxyl-
terminal domain [14]. The amino-terminal cytoplasmic domain of
LMP2A, encoded by exon 1, contains eight tyrosine (Tyr, Y)
residues, two of which (Tyr74 and Tyr85) are involved in the
formation of an immunoreceptor tyrosine-based activation motif
(ITAM) and play a crucial role in its function [15]. This motif acts
as a negative regulator of Src family and blocks B-cell receptor
(BCR)-mediated signal transduction [13,16]. A membrane prox-
imal tyrosine residue (Tyr112) binds the Lyn tyrosine kinase and
mediates the constitutive phosphorylation of the other tyrosine
residues in LMP2A [15]. LMP2A also recruits Nedd4-like
ubiquitin protein ligases to promote the degradation of Lyn and
LMP2A by an ubiquitin-dependent mechanism through phospho-
tyrosine (PY) motifs [16,17]. It has been proved that Tyr112
mutation could reduce both the degree and duration of
phosphorylation of key components of the BCR signaling cascade
[18].
Besides its function on B cells, LMP2A can also act on epithelial
cells. LMP2A induces an epithelial-mesenchymal transition and
increases the number of side population stem-like cancer cells in
NPC [19]. LMP2A is reported to transform epithelial cells, affect
cell growth and differentiation pathways in a human keratinocyte
cell line (HaCaT) [20]. LMP2A is also demonstrated to inhibit
transforming growth factor-b1-induced apoptosis in a gastric
carcinoma cell line HSC-39, through activation of the phospha-
tidylinositol-3-kinase (PI3K)-Akt pathway [21]. Moreover, recent-
ly, it is demonstrated that LMP2A up-regulates survivin gene
expression through the nuclear factor-kappa B (NF-kB) pathway in
EBVaGC [22]. In addition, LMP2A up-regulates cellular DNA
methyltransferase 1 (DNMT1) through the phosphorylation of
STAT3, causing promoter hypermethylation of a tumor suppres-
sor gene, PTEN, in EBVaGC [23]. Based on these observations, it
is conceivable that any aa change in LMP2A sequence may lead to
malfunctions of LMP2A.
LMP2A at least possesses 17 target epitopes of cytotoxic T
lymphocytes (CTLs) [24,25,26,27,28]. CTLs are very important in
controlling the long-term persistence of EBV infection; disruption
of the balance between CTL and virus-infected B cells result in
EBV-associated disease [29]. Thus, LMP2A could act as a
potential target for a CTL-based therapy for EBV-associated
malignancies [24,30,31]. Studies are very encouraging and suggest
that a CTL-based therapy may be of benefit in treating EBV-
associated malignancies [32,33]. However, according to a recently
published study [14], 9 of 16 CTL epitopes in LMP2A were
affected by at least one point mutation. These epitope mutations
may result in a reduced CTL response and confer complexity to
proposed immunotherapeutic approaches for EBV associated
malignancies.
The sequence variations of LMP2A in EBVaGC have been
explored in only two reports [14,29]. The first one is from Japan.
Tanaka et al. [29] determined the complete sequence of LMP2A in
three EBVaGC cases. In addition, the sequences of exons 2, 6 and
7 of LMP2A were determined in another one, three and two
EBVaGC cases, respectively. They found eight aa substitutions,
three of which (Y23D in exon 1, S348T in exon 6 and S444T in
exon 7) were identified in almost all cases tested. Of these three,
S348T and S444T were located within HLA A11- and A25-
restricted CTL epitopes, respectively. The other one is from
northern China. Wang et al. [14] analyzed the sequence variations
of exon 1 and exons 2–8 of LMP2A in 40 and 30 EBVaGC cases,
respectively. Thirty aa substitutions were found and 9 of 16 CTL
epitopes in LMP2A were affected by at least one point mutation.
Guangzhou, located in southern China, is well known as the
high-incidence area of NPC in the world [34]. NPC is known as an
EBV-associated epithelial malignancy. In addition, a special EBV
variant, variant-type ‘‘f’’, is predominant in NPC and is strongly
associated with NPC in Guangzhou [35,36]. In our previous study
[37], we found that the predominant EBV variant in EBVaGC in
Guangzhou was prototype F, which is different from that in NPC
in this area. Moreover, a new identified variant, mut-W1/I1
variant, which shows a T to C mutation at position 148,972 (wild
type EBV coordinates), was found in the majority of the EBVaGCs
in Guangzhou. However, this mutation could not be found in the
NPC-derived EBV stain GD1 [38]. These provide evidence that
there may be a disease-related association between EBV variants,
at least in EBVaGC versus NPC in patients drawn from the same
population. Thus, the sequence variations of LMP2A in EBVaGC
in Guangzhou were of our interest. It may be of help in clarifying
the pathogenic roles of EBV in epithelial malignancies to compare
the LMP2A variations in EBVaGC in Guangzhou with those in
NPC and in healthy EBV carrier in the same area and those in
EBVaGC in other areas.
Gastric remnant carcinoma (GRC) is defined as a carcinoma
occurring in the gastric stump at least 5 years after surgery for
benign diseases such as gastric ulcer and duodenal ulcer [39,40].
In our preliminary study, we found that the proportion of
EBVaGC in GRC was significantly higher than that in
conventional gastric carcinoma (CGC) which occurs in the intact
stomach in Guangzhou (30.8% vs. 6.7%). Similar findings were
also reported by other groups in Japan (27.1% vs. 6.4%) [41],
Korea (29% vs. 6%) [42] and Netherlands (35% vs. 8%) [43].
EBV seems more aggressive in EBVaGC in GRC than that in
CGC. However, our previous study has showed that the EBV
genome polymorphisms at the EBNA-3C region, BamHI-F
region, BamHI-W1/I1 boundary region, and exons 1 & 3 of the
LMP1 gene in EBVaGC in GRC were similar to those in
EBVaGC in CGC [44]. Are the LMP2A sequence variations in
EBVaGC in GRC different from those in EBVaGC in CGC? To
date, no study on polymorphisms of LMP2A in EBVaGC in GRC
is available.
In the present study, the sequence variations of LMP2A in
EBVaGC in CGC, EBVaGC in GRC and throat washing (TW)
samples of healthy EBV carriers in Guangzhou, southern China,
where NPC is endemic, were analyzed. We are trying to explore
the association between sequence variations of LMP2A and
EBVaGC, as well as the possibility of a CTL-based therapy for
EBVaGC.
Materials and Methods
Ethics Statement
This study was approved by the Clinical Research Ethics
Committee of the Third Affiliated Hospital, Sun Yat-sen
University. Written informed consents were taken from all the
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Declaration of Helsinki were followed.
Subjects
Six hundred and seventy-six CGC cases and twenty-six GRC
cases were collected from the Second and Third Affiliated
Hospitals of Sun Yat-sen University and the Guangzhou First
Municipal People’s Hospital, Guangzhou, China, from January 1,
2000 to December 31, 2006. All the tumor specimens were from
surgical resection cases. Paraffin blocks and clinicopathologic data,
which include age and sex of the patient, the location, histological
type, invasion depth and lymphatic and hematogenous metastases
of the tumor, were obtained from the archives of the three
Departments of Pathology. Among the 676 CGC cases, 53 cases
were early gastric carcinomas, while the remaining 623 cases were
advanced gastric carcinomas. All GRC cases were advanced
gastric carcinomas.
All GRC cases had received partial gastrectomy for reasons of
benign diseases, including gastric ulcer (16 cases), duodenal ulcer
(7 cases), combined gastric ulcer and duodenal ulcer (2 cases) and
pyloric stenosis (1 case). Cases with GRC after gastrectomy for
gastric cancer were excluded in this study.
Histology of the gastric carcinomas was classified as intestinal-
and diffuse-type according to the Lauren classification [45]. The
tumor location and depth of invasion were classified according to
the Japanese classification [46].
TW samples from 50 healthy donors were also collected in the
same geographical regions by gargling with 15 ml of phosphate
buffered saline (PBS). Polymerase chain reaction (PCR) with the
BamHI K region primers was used to screen the TWs for EBV
genome. Seventeen (34%) of the 50 TW samples were positive for
the EBV BamHI K fragment.
All the patients and healthy donors were inhabitants in
Guangdong province with local dialects.
Construction of tumor tissue microarrays
The tumor tissue microarray (TMA) blocks were constructed as
described by Kononen et al. [47]. A 1268 cylinder matrix was
defined on a 3.562.5 cm
2 paraffin wax block, and position-specific
blank cylinders were adopted for orientation during microscopy
analysis. A total of 14 TMA blocks were constructed, where each
TMA block contained up to 94 tissue cores from 47 cases of
advanced gastric carcinoma and each case was composed of 2
tissue cores. An adequate case was defined by tumor occupancy of
more than 10% of the core area.
In situ hybridization
An in situ hybridization (ISH) assay was performed on the TMA
sections, as well as the donor block sections of the positive tissues
on the TMA sections, and on the block sections of early gastric
carcinoma cases with a commercially available EBV oligonucle-
otide probe complementary to the EBV-encoded small RNA-1
(EBER-1) (PanPath, Amsterdam, Netherlands), according to the
manufacturer’s instructions. The hybridization signals were
visualized with 3,39-diaminobenzidine (DAB; Vector Laboratories,
Inc.), and positive signals were recognized as dark brown nuclear
staining under light microscopy. Sections from a known EBER-1-
positive NPC tissue were used as the positive control and a sense
probe for EBER-1 was used as the negative control.
Immunostaining for LMP2A
The immunostaining for LMP2A was performed using the two-
step EnVision immunohistochemical procedure (Dako, Denmark)
as previously described [44]. The monoclonal antibody against
LMP2A (clone 4A11B3A3; a gift from Prof. Mu-sheng Zeng) [19]
was applied. The signals were visualized with DAB, and the slides
were counterstained with Mayer’s hematoxylin. The LMP2A-
positive NPC tissues were used as positive controls. PBS other than
the primary antibodies was used as the negative control. Tumors
were considered positive if 10% or more of the neoplastic cells
were stained.
DNA extraction
Total DNA was extracted from EBV positive paraffin sections
and TW samples of healthy donors using the NucleoSpin Tissue
Kit (MACHEREY-NAGEL GmbH & Co. KG, Du ¨ren, Germany)
according to the manufacturer’s instructions. Paraffin blocks
without any samples were used as negative controls throughout
the procedures. EBV-positive cell line B95.8 was used as positive
control. The extracted DNA sample was dissolved in 100 mlo fT E
buffer.
Polymerase chain reaction
PCR was performed with 2 ml of DNA in a 50 ml total reaction
mixture containing 10 mM Tris-HCl (pH 8.0), 50 mM KCl,
1.5 mM MgCl2, 200 mM dNTP, 0.5 mM of each primer and
1.25 U Taq Polymerase (TaKaRa, Dalian, China). EBV BamHI K
region and exons 1–8 of LMP2A were amplified. Exon 9 of
LMP2A was not amplified in the present study, because neither
functional domain nor sequence variation was detected in this
fragment [29]. The primers are listed in Table 1. The
amplification protocol was one cycle at 95uC for 5 min, followed
by 40 cycles of denaturation at 95uC for 1 min, annealing at 55uC
for 1 min and elongation at 72uC for 1 min, and a final extension
at 72uC for 10 min. The amplified products were detected on 2%
agarose gels stained with 0.5 mg/ml of ethidium bromide and
photographed under UV light.
DNA sequencing
The products of the PCR reaction were extracted and purified
using QIAquick PCR Purification Kit (QIAGEN, Hilden,
Germany). The purified PCR products were then subjected to
DNA sequencing. Cycle sequencing was carried out using the ABI
PRISM BigDye Terminator Cycle Sequencing Ready Reaction
Kit (PE Applied Biosystems, CA, USA) according to the
manufacturer’s manual. Sequence analysis was performed on the
3730xl DNA Analyzers and the data were analyzed with Seq Ed.
software (PE Applied Biosystems). All sequences were performed
uni-directionally. The results were then compared with the
sequences of EBV strains B95.8 (GenBank Accession No.:
V01555) and GD1 (GenBank Accession No.: AY961628).
Statistical analysis
Fisher’s exact test or Student’s t test was used for statistical
analysis in the present study. The results were considered to be
statistically significant at a p-value of less than 0.05. All the p-values
presented in the present study are two-sided.
Results
EBER-1 expressed in 6.7% CGCs and 30.8% GRCs
Forty-five (6.7%) out of the 676 CGC cases and 8 (30.8%) out of
the 26 GRC cases displayed EBER-1 ISH positive signals
(Figure 1A,B) and were considered EBVaGCs. In most EBVaGC
cases, the positive signals were restricted only to the nuclei of
carcinoma cells. However, in three EBVaGC cases in CGC, some
dysplastic epithelial cells adjacent to the carcinoma also showed
Variations of LMP2A in EBVaGC in Southern China
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around the carcinoma tissues showed negative signals.
The clinicopathologic features of EBVaGC in CGC and GRC
are shown in Table 2.
LMP2A expressed in 53.3% EBVaGCs in CGC and 62.5%
EBVaGCs in GRC
The immunohistochemistry of LMP2A was performed in all 53
EBVaGC cases. Twenty-four (53.3%) of the 45 EBVaGC cases in
CGC and 5 (62.5%) of 8 EBVaGC cases in GRC showed diffuse
positive signals in the membrane and cytoplasm of the tumor cells
(Figure 1C,D).
There was no correlation between LMP2A expression and the
clinicopathologic parameters of EBVaGC, which include the age
and sex of the patient, the location, histology and stage of the
tumor (all p.0.05, data not shown).
Sequence variations of LMP2A exon 1 in EBVaGC in CGC,
EBVaGC in GRC and TW of healthy EBV carriers
LMP2A exon 1 was successfully amplified in 45 EBVaGCs in
CGC, 8 EBVaGCs in GRC and 17 TWs of healthy EBV carriers.
All sequences were compared with the B95.8 prototype sequence.
Six loci of nucleotide substitution were identified, 4 of which result
in aa changes. Among them, the nucleotide mutation (tRg) at
position 166627, which results in a YRD substitution at aa 23,
was detected in 35 (77.8%) EBVaGCs in CGC, 8 (100%)
EBVaGCs in GRC and 17 (100%) TWs of healthy EBV carriers.
The distribution of nucleotide variations of LMP2A exon 1 in
EBVaGC in CGC, EBVaGC in GRC and TW of healthy EBV
carriers was shown in Table 3.
Table 1. Primers used in the present study.
Transcript Product Size Sequence (59-39)
B95.8 Genomic
Coodinates Reference
BamHI K 270 bp 59 primer GTCATCATCATCCGGGTCTC 109110–109129
39 primer TTCGGGTTGGAACCTCCTTG 109379–109360
Exon 1a* 279 bp 59 primer CGGTTTCAGCATCACAGG 166451–166468
39 primer GGGGCTCTTCATTAGATTCACG 166729–166708
Exon 1b* 327 bp 59 primer CCATCTGCTTCTGGCTCTT 166654–166672
39 primer CGCCCTTATTATTGATGTGA 166980–166961
Exon 2 292 bp 59 primer TTGCTCTATTCACCCTTACT 11–30 [29]
39 primer ATGCATTGTAAATGGTGCGT 302–283
Exon 3 159 bp 59 primer ACAGTTCACTTCCTCTGCTT 330–349 [29]
39 primer ACCTGCATTTCATAACAGAG 488–469
Exon 4 309 bp 59 primer GGCATGACGTCAACTTTACT 510–529 [29]
39 primer AAGGCAAGCAATGTCACACG 818–799
Exon 5 141 bp 59 primer CAGGACTAACCATGCCATCT 841–860 [29]
39 primer AGTAATGAGTTAAAGGAAGG 981–962
Exon 6 283 bp 59 primer AATCGCAGCTCTAACTTGGC 993–1012
39 primer GGAACAAAGCGTAAAATGTGTG 1275–1254
Exon 7 285 bp 59 primer CTATTGGATTGTAACACACA 1240–1259 [29]
39 primer AAGGCAACACCTGTTGGTGT 1524–1505
Exon 8 177 bp 59 primer ACATGACTTACATGGGTTTG 1544–1563 [29]
39 primer TACACGTGATAGTGTCTCTA 1720–1701
*Exon 1 was amplified as two fragments because the whole fragment was too long for DNA amplification in paraffin-embedded tissue. Exon 1a and exon 1b were
overlapped so they together covered the whole exon 1 fragment.
doi:10.1371/journal.pone.0034276.t001
Figure 1. Expression of LMP2A in EBVaGC. (A) H&E staining of a
moderate differentiated tubular gastric adenocarcinoma. The histology
of this case was intestinal-type carcinoma according to the Lauren
classification. (Original magnification 6200). (B) EBER-1 in situ hybrid-
ization of the same case. The EBER-1-positive signals were restricted
only to the tumor nuclei but not in surrounding non-tumor cells.
(Original magnification 6200). (C) Immunohistochemistry staining for
LMP2A of the same case. Positive staining can be seen in the tumor cells
but not in infiltrating lymphocytes in and around the tumor nests.
(Original magnification 6200). (D) Higher magnification of panel C.
Positive signals of LMP2A were labeled in the cytoplasm and membrane
of the tumor cells. (Original magnification 6400).
doi:10.1371/journal.pone.0034276.g001
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CGC,EBVaGC in GRC and TW of healthy EBV carriers
DNA sequences of LMP2A exons 2–8 were obtained from 36
EBVaGCs in CGC, 8 EBVaGCs in GRC and 17 TWs of healthy
EBV carriers, respectively. In total, 39 nucleotide mutations were
found, which cause 18 aa changes. Among them, 12 loci of aa
mutation (codons 153, 169, 171, 208, 248, 254, 255, 350, 370,
391, 426 and 444) were detected in .40% isolates from both
EBVaGCs in CGC and TWs of healthy EBV carriers. The
distribution of these mutations between EBVaGCs in CGC and
TWs of healthy EBV carriers did not differ significantly (p.0.05).
In EBVaGCs in GRC, aa mutations at codons 153, 169, 171, 208,
370, 391, 426 and 444 were found in .40% cases, while at codon
350, the I to V substitution was detected in 37.5% of the cases.
The distribution of these mutations between EBVaGCs in CGC
and EBVaGCs in GRC did not differ significantly, either
(p.0.05). At codons 248, 254 and 255, no aa mutation was
detected in EBVaGCs in GRC. The difference of these mutation
between EBVaGCs in GRC and EBVaGCs in CGC was
statistically significant (p=0.014). At aa 348, 6 (16.7%) EBVaGCs
in CGC, 4 (50%) EBVaGCs in GRC and 9 (52.9%) TWs of
healthy EBV carriers harbored an S to T substitution. The
difference of this mutation between EBVaGCs in CGC and TWs
of healthy EBV carriers was statistically significant (p=0.010).
However, the distributions of this mutation between EBVaGCs in
CGC and EBVaGCs in GRC as well as between EBVaGCs in
GRC and TWs of healthy EBV carriers did not differ significantly
(p=0.064 and 1.000, respectively). The sequences of exons 5 and 8
were identical with those of B95.8, that is, no variation was
detected in these two fragments. The distribution of nucleotide
variations of LMP2A exons 2–8 in EBVaGC in CGC, EBVaGC
in GRC and TW of healthy EBV carriers was shown in Table 4.
ITAM, PY motifs in the amino terminus of LMP2A were
strictly conserved
Several functional critical motifs, including ITAM, PY motifs,
were identified in the amino terminus of LMP2A. Their sequence
polymorphisms were analyzed in the present study. The ITAM,
consisting of paired pivotal tyrosines and leucines (YxxL) at Y74
and Y85, was conserved in all isolates. The two PY motifs (PPPPY
Y60 and Y101), were not affected by mutations in any isolates,
either.
Table 2. Clinicopathologic characteristics of EBVaGC in CGC
and GRC.
Variables EBVaGC in CGC (n) EBVaGC in GRC (n) p*
Gender
Male 37 8 0.333
Female 8 0
Age (years)
#40 11 0 0.181
.40 34 8
Range 23,76 55,79
Mean 6 SD
{ 51.5613.9 67.667.4 0.000
Location
{
Cardia 15 /
Body 14 /
Antrum 14 /
Whole
1 2/
Stump / 8
Histology
I
Intestinal 8 0 0.333
Diffuse 37 8
Invasion
{
T1 0 0 1.000
T2 4 0
T3 35 7
T4 6 1
Stage (pTNM)
{
1a 0 0 0.442
1b 1 0
28 3
3a 15 4
3b 9 0
41 2 1
*p-values were obtained from Fisher’s exact tests or Student’s t tests.
{SD: standard deviation.
{Japanese classification.
1Cases involved the whole stomach.
ILauren classification.
doi:10.1371/journal.pone.0034276.t002
Table 3. Distribution of nucleotide variations of LMP2A exon 1 in EBVaGC in CGC, EBVaGC in GRC and TW of healthy EBV carriers.
Nucleotide Amino acid No. of isolates (%)
EBVaGC
in CGC
(n=45)
EBVaGC
in GRC
(n=8)
TW of healthy EBV
carriers
(n=17)
Exon 1 166604 gRa* 15 SRN 1(2.2) 0(0) 4(23.5)
166627 tRg* 23 YRD 35(77.8) 8(100.0) 17(100.0)
166796 cRa* 79 TRN 3(6.7) 0(0) 0(0)
166805 aRc* 82 QRP 3(6.7) 0(0) 0(0)
166810 cRt8 4 L RL 3(6.7) 0(0) 0(0)
166896 cRt1 1 2 Y RY 15(33.3) 0(0) 0(0)
*missense mutation.
doi:10.1371/journal.pone.0034276.t003
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In the present study, 8 of the 17 identified CTL epitopes were
affected by at least one point mutation. The distributions of aa
variations of CTL epitopes in EBVaGC in CGC, EBVaGC in
GRC and TW of healthy EBV carriers were summarized in
Table 5. Among the mutant CTL epitopes, the HLA-A11-
restricted CTL epitope (codons 340 to 350) identified two
mutations: S348T and I350V. The first mutation was detected
in 16.7% (6/36) of EBVaGCs in CGC, 50% (4/8) of EBVaGCs in
GRC and 52.9% (9/17) of TWs of healthy EBV carriers, while the
Table 4. Distribution of nucleotide variations of LMP2A exons 2–8 in EBVaGC in CGC, EBVaGC in GRC and TW of healthy EBV
carriers.
Nucleotide Amino acid No. of isolates (%)
EBVaGC
in CGC
(n=36)
EBVaGC
in GRC
(n=8)
TW of healthy EBV
carriers
(n=17)
Exon 2 100 cRg1 3 3 L RL 28(77.8) 6(75) 17(100%)
133 cRt1 4 4 F RF 0(0) 0(0) 1(5.9)
157 gRc1 5 2 V RV 19(52.8) 4(50) 8(47.1)
158 aRc* 153 TRP 1(2.8) 0(0) 0(0)
159 cRg* 153 TRS 19(52.8) 4(50) 8(47.1)
185 aRc1 6 2 L RL 1(2.8) 0(0) 0(0)
196 aRc1 6 5 A RA 1(2.8) 0(0) 0(0)
207 gRa* 169 SRN 21(58.3) 7(87.5) 9(52.9)
213 aRc* 171 YRS 19(52.8) 4(50) 8(47.1)
247 gRt1 8 2 V RV 19(52.8) 4(50) 8(47.1)
250 aRc1 8 3 L RL 1(2.8) 0(0) 0(0)
253 gRt1 8 4 V RV 25(69.4) 7(87.5) 17(100)
Exon 3 391 gRa2 0 1 E RE 28(77.8) 6(75) 9(52.9)
410 cRa* 208 LRI 28(77.8) 6(75) 9(52.9)
Exon 4 571 gRa2 3 4 A RA 20(55.6) 2(25) 10(58.8)
579 gRc* 237 RRT 1(2.8) 0(0) 0(0)
599 gRc* 244 VRL 1(2.8) 0(0) 0(0)
613 cRg* 248 IRM 18(50) 0(0) 7(41.2)
629 gRc* 254 VRL 18(50) 0(0) 7(41.2)
632 cRg* 255 LRV 18(50) 0(0) 7(41.2)
Exon 6 1068 gRc* 348 SRT 6(16.7) 4(50) 9(52.9)
1073 cRg* 350 IRV 17(47.2) 3(37.5) 7(41.2)
1075 cRt* 17(47.2) 3(37.5) 7(41.2)
1105 cRa3 6 0 L RL 19(52.8) 5(62.5) 9(52.9)
1134 tRc* 370 IRT 19(52.8) 5(62.5) 9(52.9)
1138 tRc3 7 1 A RA 17(47.2) 3(37.5) 7(41.2)
1177 cRt3 8 4 S RS 17(47.2) 3(33.3) 7(41.2)
1182 cRg* 386 TRS 1(2.8) 0(0) 0(0)
1195 cRt3 9 0 P RP 17(47.2) 3(37.5) 7(41.2)
1196 aRc* 391 SRR 19(52.8) 5(62.5) 9(52.9)
Exon 7 1302 gRc3 9 8 L RL 0(0) 1(12.5) 0(0)
1323 cRt4 0 5 F RF 16(44.4) 3(37.5) 11(64.7)
1350 cRa4 1 4 G RG 23(63.9) 4(50) 13(76.5)
1374 aRc4 2 2 P RP 24(66.7) 6(75) 13(76.5)
1385 gRc* 426 CRS 23(63.9) 4(50) 13(76.5)
1389 cRt4 2 7 L RL 2(5.6) 0(0) 0(0)
1392 tRc4 2 8 G RG 23(63.9) 4(50) 13(76.5)
1435 aRg* 443 MRV 1(2.8) 0(0) 0(0)
1438 tRa* 444 SRT 29(80.6) 7(87.5) 15(88.2)
No nucleotide variation was detected in exons 5 and 8 of LMP2A.
*missense mutation.
doi:10.1371/journal.pone.0034276.t004
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CGC, 37.5% (3/8) of EBVaGCs in GRC and 41.2% (7/17) of
TWs of healthy EBV carriers. The distribution of these mutations
between EBVaGCs in CGC and TWs of healthy EBV carriers was
statistically significantly different (p=0.009), while that between
EBVaGCs in CGC and EBVaGCs in GRC and that between
EBVaGCs in GRC and TWs of healthy EBV carriers were not
statistically significantly different (p=0.121 and 1.000, respective-
ly).
Discussion
The present study not only described the expression of LMP2A
in EBVaGC but also for the first time revealed the polymorphisms
of LMP2A in EBVaGC in Guangzhou, southern China, which is
an endemic area of NPC. Widespread sequence variations in the
LMP2A gene were found, with no sequence identical to the B95.8
prototype. No consistent mutation was detected in all isolates. The
ITAM and PY motifs in the amino terminus of LMP2A were
strictly conserved, while 8 of the 17 identified CTL epitopes were
affected by at least one point mutation.
In the present study, LMP2A was detected in 53.3% (24/45) of
the EBVaGC cases in CGC and 62.5% (5/8) of the EBVaGC
cases in GRC by immunohistochemistry (IHC). zur Hausen et al.
[10], Sugiura et al. [11] and Luo et al. [12] examined the viral gene
expression in EBVaGCs at the mRNA level and found that
LMP2A mRNA was detected in 7 of 9 (77.8%), 3 of 7 (42.9%) and
4 of 11 (36.4%) cases, respectively. The different detection rates of
LMP2A in EBVaGC may relate to the sentitivity of detection
methods used. Using reverse transcription-PCR (RT-PCR),
LMP2A mRNA was detected in 14 of 27 (51.9%) EBVaGC cases
in total. By IHC, LMP2A expression was found in 29 of 53
(54.7%) EBVaGC cases in total. The detection rates of LMP2A in
EBVaGC by RT-PCR and IHC are similar. These findings
indicate that LMP2A is expressed in about half of the EBVaGC
cases, irrespective of the detection methods used. Thus, EBVaGC
could be divided into two subgroup based on the LMP2A
expression. The first subgroup of EBVaGC does not express
LMP2A, whose EBV latency pattern is the same with that of
Burkitt lymphoma (latency I) [48]. The second subgroup of
EBVaGC expresses LMP2A; thus, its EBV latency pattern is
somewhat different from the conventional latency I represented by
Burkitt lymphoma [48], and may represent a novel EBV latency
pattern. Since LMP2A has been demonstrated to play important
roles in the oncogenic processes in EBVaGC [22,23], and about
half of the EBVaGCs express LMP2A, we suggest designating the
EBV latency pattern in EBVaGC as latency Ia and Ib, based on
the absence and presence of LMP2A expression, respectively.
In the amino terminus of LMP2A, six nucleotide mutations and
four resultant aa changes were found in EBVaGC in CGC. These
four loci of aa substitution were also found in EBVaGC in
northern China [14]. However, except for aa 23, the other three
loci were not detected in 3 EBVaGCs in Japan [29]. Y23 is one of
the eight tyrosine residues located in the amino terminus of
LMP2A. The Y to D substitution at aa 23 was detected in 77.8%
(35/45) EBVaGCs in CGC, 100% (8/8) EBVaGCs in GRC and
100% (17/17) TWs of healthy EBV carriers in the present study. It
was also detected in all isolates from EBVaGC in Japan (3/3) [29]
Table 5. Amino acid variations of CTL epitopes in EBVaGC in CGC, EBVaGC in GRC and TW of healthy EBV carriers.
HLA
restriction
LMP2A
residues Epitope sequence No. of isolates (%)
EBVaGC in
CGC (n=36)
EBVaGC in
GRC (n=8)
TW of healthy
EBV carriers
(n=17)
ND* 141–154 A S C F T A S V S T V V T A 16(44.4) 4(50) 9(52.9)
– – – – – – – – – – – – P – 1(2.8) 0(0) 0(0)
– – – – – – – – – – – – S – 19(52.8) 4(50) 8(47.1)
B60 200–208 I E D P P F N S L 8(22.2) 2(25) 8(47.1)
– – – – – – – – I 28(77.8) 6(75) 9(52.9)
B27 236–244 R R R W R R L T V 35(97.2) 8(100) 17(100)
– T – – – – – – L 1(2.8) 0(0) 0(0)
ND* 249–262 M F L A C V L V L I V D A V 18(50) 8(100) 10(58.8)
– – – – – L V – – – – – – – 18(50) 0(0) 7(41.2)
A11 340–350 S S C S S C P L S K I 13(36.1) 1(12.5) 1(5.9)
– – – – – – – – T – – 6(16.7) 4(50) 9(52.9)
– – – – – – – – – – V 17(47.2) 3(37.5) 7(41.2)
A24 419–427 T Y G P V F M C L 13(36.1) 4(50) 4(23.8)
– – – – – – – S – 23(63.9) 4(50) 13(76.5)
A2 426–434 C L G G L L T M V 13(36.1) 4(50) 4(23.8)
S – – – – – – – – 23(63.9) 4(50) 13(76.5)
A25 442–451 V M S N T L I S A W 6(16.7) 1(12.5) 2(11.8)
– V – – – – – – – – 1(2.8) 0(0) 0(0)
– – T – – – – – – – 29(80.6) 7(87.5) 15(88.2)
Sequences listed are epitope sequences of the B95.8 prototype. Only the mutant amino acids are shown; ‘‘–’’ indicates sequence identical to B95.8.
*ND: Not determined.
doi:10.1371/journal.pone.0034276.t005
Variations of LMP2A in EBVaGC in Southern China
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34276and in northern China (40/40) [14]. In addition, 100% (36/36)
NPCs and 100% (40/40) TWs of healthy EBV carriers from
northern China harbored this mutation, too [14]. Moreover,
Y23D was also detected in all isolates from 8 NPCs (one from
Egypt, one from continental USA, one from Alaska, three from
China, and two from Malaysia), 4 post-transplant lymphomas
from the Unite States, 2 Burkitt lymphomas (one from Central
Africa and one from continental USA/Mediterranean Africa),
irrespective of either disease type or geographical origin [49].
Furthermore, the tyrosine (Y23) is not found in the LMP2A-like
protein sequence of herpesvirus papio from baboons [50].
Therefore, the amino acid substitution (YRD) at codon 23 might
not affect LMP2A functions. Aside from this substitution, the other
seven tyrosine residues (Y31, Y60, Y64, Y74, Y85, Y101, and
Y112) were all conserved in all the isolates. Thus, the ITAM and
PY motifs were strictly conserved in EBVaGC and TW of healthy
EBV carriers, indicating their critical role in the maintenance of
gene functions.
In the transmembrane region (exons 2–8) of LMP2A, 39
nucleotide mutations were found, which cause 18 aa changes.
Except for T153P and M443V, the other 16 aa substitutions were
also detected in EBVaGC in northern China [14]. As we know,
the important domains in the transmembrane region of LMP2A
are targets of EBV-specific CTLs [24,25,26,27,28]. CTLs are very
important in controlling the long-term persistence of EBV
infection [29]. It is demonstrated that EBVaGC have much more
CD8+ CTL infiltrate than EBV-negative gastric carcinoma
(EBVnGC) [51,52], and that EBVaGC generally have lower
frequency of lymph node metastases and better prognosis,
suggesting a protective role for the CTL infiltrate [52]. Mutation
of the targets would be expected to affect the CTL response to cells
expressing LMP2A and result in a growth advantage of the cells in
the host [29]. In the present study, 8 of 17 CTL epitopes displayed
mutations. Wang et al. [14] also reported 9 CTL epitopes
mutations in LMP2A from 30 EBVaGCs in northern China,
which included the 8 mutant CTL epitopes identified in the
present study. The high frequency of CTL epitopes mutation may
reduce or abrogate CTL responses [53,54], and confer an
advantage on EBV for immune escape and virus persistence in
tumor cells, thus playing a role in tumorigenesis and tumor
maintenance [29]. However, one point should be noted is that
some aa changes in CTL epitopes are conservative in nature (i.c.
S348T, I350V) or in non-anchoring positions and thus may not
affect MHC-I binding or T-cell receptor (TCR) recognition
dramatically [24]. Therefore, whether the mutations in putative
CTL epitopes on LMP2A indeed affect functional recognition and
thus play a role in immune selection should be confirmed in
functional assays (such as IFN-c ELISPOT assay).
Among the mutant CTL epitopes, the HLA-A11-restricted
CTL epitope (codons 340 to 350) was of our great interest. The
serine (S) to threonine (T) mutation at aa 348 was detected in
52.9% (9/17) of TWs of healthy EBV carriers in the present
study. Tanaka et al. [29] and Wang et al. [14] also found that S or
T at codon 348 was almost equally distributed in EBV isolates
from healthy individuals in Japan and northern China,
respectively. On the other hand, in the present study, only
6.7% (6/36) of EBVaGCs in CGC harbored this mutation
(S348T). However, in northern China, S or T at codon 348 was
almost equally observed in EBVaGC [14], while in Japan, the
S348T mutation was predominant in EBVaGC [29]. These
suggested that the polymorphisms at aa 348 may represent
geographic or race-associated polymorphisms rather than disease-
associated ones.
Another CTL epitope which was also of our interest is the HLA-
A25-restricted CTL epitope (codons 442 to 451). In the present
study, an S to T mutation at aa 444 was observed in the majority
of specimens, including 80.6% (29/36) EBVaGCs in CGC, 87.5%
(7/8) EBVaGCs in GRC and 88.2% (15/17) TWs of healthy EBV
carriers. To date, all EBV isolates from EBVaGC in northern
China (30/30) [14] and Japan (5/5) [29] harbored this mutation.
Besides, all EBV isolates from NPC and healthy individuals in
northern China also showed this mutation [14]. In addition to the
S444T mutation which was reported previously, M443V was
firstly identified in one EBVaGC case in CGC in the present
study.
Another interesting finding in the present study is that the
exons 5 and 8 of LMP2A were strictly conserved among
EBVaGCs and TWs of healthy EBV carriers. They were also
conserved in all isolates from EBVaGC in Japan (3/3) [29] and
northern China (30/30) [14]. In addition, 100% (31/31) NPCs
and 100% (44/44) TWs of healthy EBV carriers in northern
China showed conserved sequences in exons 5 and 8 of LMP2A,
too. Exon 8 of LMP2A does not contain any known CTL
epitope, while exon 5 contains a HLA-A2-restricted CTL epitope
(codons 329 to 337). This epitope was conserved in all isolates
from eight Caucasian Hodgkin lymphoma patients and seven
southern Chinese NPC patients [24]. Besides, the epitope was
also conserved among EBV isolates derived from the peripheral
blood of five Caucasian/African, two New Guinean and two
southern Chinese donors [24]. These findings suggested that this
epitope might be served as an effective target for CTL therapy for
EBV-associated malignancies.
It is known that the proportion of EBVaGC in GRC was
significantly higher than that in CGC [41,42,43,44]. Given that,
EBV seems more aggressive in EBVaGC in GRC than that in
CGC. Are the LMP2A sequence variations in EBVaGC in GRC
different from those in EBVaGC in CGC? In the present study, we
found that in most loci of aa mutation, the number of mutations in
EBVaGCs in GRC is similar to that in EBVaGCs in CGC.
However, at aa codons 248, 254 and 255, which located in exon 4
of LMP2A, no mutation was detected in EBVaGCs in GRC; while
aa mutation at these 3 codons were detected in 50% EBVaGCs in
CGC. The difference of these mutation between EBVaGCs in
GRC and EBVaGCs in CGC was statistically significant
(p=0.014). Besides, S348T mutation was detected in 50%
EBVaGCs in GRC and 16.7% EBVaGCs in CGC. The difference
of this mutation between EBVaGCs in GRC and EBVaGCs in
CGC was of borderline statistically significance (p=0.064).
Therefore, the LMP2A sequence variations in EBVaGC in
GRC seem somewhat different from those in EBVaGC in CGC.
However, this may be caused by the relative small sample size in
EBVaGC in GRC. Larger sample size is needed to draw a definite
conclusion.
In conclusion, the present study revealed the LMP2A
p o l y m o r p h i s m si nE B V a G Ci nb o t hC G Ca n dG R Cf r o m
southern China, an endemic area of NPC. The sequence
variations of LMP2A in EBVaGC were similar to those in TW
of healthy EBV carriers, indicating that these variations were
due to geographic-associated polymorphisms rather than
EBVaGC-associated mutations. The ITAM and PY motifs in
the amino terminus of LMP2A were strictly conserved,
suggesting their important roles in virus infection, while CTL
epitopes mutations in the transmembrane region of LMP2A
may implicate that the effect of LMP2A polymorphisms
should be considered when LMP2A-targeted immunotherapy
is conducted.
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